Background
Phase III RCT (RTOG 0129) comparing two RT fractionation schedules in LA HNSCC. N=743, oropharyngeal (70%), larynx, hypopharynx, oral cavity; stages III–IV. Standard fractionation (SF: 70 Gy/35 fx + cisplatin) vs accelerated fractionation with concomitant boost (ACB: 72 Gy/42 fx + cisplatin). Post-hoc landmark HPV-prognosis analysis on 323 oropharyngeal patients with tumor samples.
Interventions and follow up
Arm A: Cisplatin 100 mg/m² D1, D22 + standard fractionation RT (70 Gy/35 fx over 7 wk)
Arm B: Cisplatin 100 mg/m² D1, D22 + accelerated concomitant boost RT (72 Gy/42 fx over 6 wk)
Primary endpoint: OS (fractionation comparison)
Arm B: Cisplatin 100 mg/m² D1, D22 + accelerated concomitant boost RT (72 Gy/42 fx over 6 wk)
Primary endpoint: OS (fractionation comparison)
Results
3-year OS (SF vs ACB): 64.3% vs 63.5%, P=.67 — no fractionation benefit
HPV+ 3-year OS (oropharynx): 82.4% vs HPV-negative 57.1%, HR for death 0.42 (95% CI 0.27–0.66), P<.001
HPV+ 3-year PFS: 73.7% vs 43.4% (HPV-), P<.001
Smoking interaction: HPV+ heavy smokers (≥10 pack-year) intermediate prognosis between HPV+ light smokers and HPV-
HPV+ 3-year OS (oropharynx): 82.4% vs HPV-negative 57.1%, HR for death 0.42 (95% CI 0.27–0.66), P<.001
HPV+ 3-year PFS: 73.7% vs 43.4% (HPV-), P<.001
Smoking interaction: HPV+ heavy smokers (≥10 pack-year) intermediate prognosis between HPV+ light smokers and HPV-
Adverse events
Grade ≥3 acute AEs: ~83% in both arms (cisplatin-based); no differential by fractionation
Predominant: mucositis, dysphagia, leukopenia
Predominant: mucositis, dysphagia, leukopenia
Conclusions
Standard and accelerated concomitant boost fractionation with cisplatin produced equivalent survival. The pivotal finding: HPV positivity (p16+ surrogate) conferred dramatically better prognosis in oropharyngeal cancer (3-year OS 82% vs 57%), with smoking as a modifying factor. HPV status is now the most important prognostic variable in OPC.
Key Limitations
HPV analysis retrospective on available samples (323/743); no prospective HPV data. Causality vs confounding not fully separable (HPV+ patients younger, fewer comorbidities). p16 IHC (not HPV ISH) used, with some false-positive rate. The fractionation comparison itself was negative.
Clinical Context
With Chaturvedi (2011) and Fakhry (JCO 2008), established HPV as the defining prognostic factor in OPC. Led to HPV-stratified enrollment in subsequent HNSCC trials, AJCC-8 staging for p16+ OPC, and the de-escalation research agenda. ASCO and ESMO now recommend p16 testing for all oropharyngeal SCC at diagnosis.
References